% IMPORTANT: The following is UTF-8 encoded. This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.
@ARTICLE{Sauer:289215,
author = {C. Sauer and S. Zschäbitz and J. Krauss and T. Walle$^*$
and G. M. Haag$^*$ and D. Jäger$^*$ and K. Hiller and T. J.
Bugaj and H.-C. Friederich and I. Maatouk},
title = {{E}lectronic health intervention to manage symptoms of
immunotherapy in patients with cancer ({SOFIA}): {R}esults
from a randomized controlled pilot trial.},
journal = {Cancer},
volume = {130},
number = {14},
issn = {0008-543X},
address = {New York, NY},
publisher = {Wiley-Liss},
reportid = {DKFZ-2024-00649},
pages = {2503-2514},
year = {2024},
note = {2024 Jul 15;130(14):2503-2514},
abstract = {For patients receiving immune checkpoint inhibitors, early
detection of immune-related adverse events (irAEs) is
critical for one's safety. To this end, a smartphone app
(SOFIA) was developed that featured the assessment of
electronic patient-reported outcomes (ePROs) focusing on
irAEs as well as a set of comprehensive supportive
information. Its feasibility and preliminary efficacy were
evaluated in a randomized controlled trial (RCT).Patients
who received immune checkpoint inhibition therapy were
randomly assigned to an intervention group (IG) or a control
group (CG; care as usual). During the 12-week intervention
period, IG patients used SOFIA to report twice weekly ePROs
and receive cancer- and immunotherapy-relevant contents.
Before a patient's next clinical visit, the physician in
charge was given the ePRO reports. The primary objective was
to test the feasibility of SOFIA. Furthermore, the
preliminary efficacy of SOFIA for health-related quality of
life (HRQOL), psychosocial outcomes, and medical data was
examined. Clinical outcomes were assessed at baseline (T0),
post-intervention (T1), and a 3-month follow-up
(T2).Seventy-one patients were randomized to the IG (n = 34)
or the CG (n = 37). SOFIA showed high feasibility and
acceptance. At T1, patients in the IG reported significantly
better HRQOL and role functioning and less depression,
distress, and appetite loss. No significant differences were
revealed regarding medical data, the utilization of
supportive care services, or survival.SOFIA showed high
feasibility and acceptance and improved HRQOL and
psychosocial outcomes. These results suggest further
evaluation of efficacy in a large-scale confirmatory
multicenter RCT.},
keywords = {cancer (Other) / electronic health (eHealth) (Other) /
electronic patient‐reported outcomes (ePROs) (Other) /
immunotherapy (Other) / mobile health (mHealth) (Other) /
psycho‐oncology (Other)},
cin = {F230 / D490 / D120 / HD01},
ddc = {610},
cid = {I:(DE-He78)F230-20160331 / I:(DE-He78)D490-20160331 /
I:(DE-He78)D120-20160331 / I:(DE-He78)HD01-20160331},
pnm = {314 - Immunologie und Krebs (POF4-314)},
pid = {G:(DE-HGF)POF4-314},
typ = {PUB:(DE-HGF)16},
pubmed = {pmid:38564338},
doi = {10.1002/cncr.35300},
url = {https://inrepo02.dkfz.de/record/289215},
}